ASBMR
<ѻý class="page-description">American Society for Bone and Mineral Researchѻý>Phase I study shows ability to modulate cell signaling
Areal BMD increased when given at the start of maximal estradiol depletion therapy
Further bad news for omega-3 fatty acids in VITAL trial analysis
High or low levels made no difference among healthy people
Large observational databases mitigate concerns about the osteoporosis therapy
Algorithm held its own, but not many study patients were on biologics
Incidence has declined, but burden will increase as older population grows
Same peptide formulated for oral administration passes phase II test
Novel agent, aimed at doing away with adverse metabolic effects, proves mettle in DMD
Updates reflect evidence accumulated in recent years, though research needs remain
Landmark trial throws more cold water on vitamin D, omega-3 pills
Favorable results on most outcomes may suggest poor choice of primary
Weight change in type 2 diabetes on these drugs did not increase risk of osteoporotic fractures
Absolute risk was low for patients receiving zoledronic acid versus denosumab
-
AAOS: American Academy of Orthopaedic Surgeons
February 2024
-
ASBMR: American Society for Bone and Mineral Research
September 2022